Anika Therapeutics Announces Leadership Transition GlobeNewswire January 08, 2026 Stephen (Steve) Griffin, Current Chief Financial Officer and Chief Operating Officer, Appointed President and Chief Executive Officer Cheryl Blanchard to Become Executive Chair of the Board of Directors BEDFORD, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the […]
ONAR Completes Sale of Certain Legacy Assets in a Secured $1.5 Million Seller-Financed Transaction The agreement converts certain legacy assets into a structured payment obligation supported by collateral and a personal guaranty, while expressly excluding intellectual property related to the 'Of Kos' brand from the sale. The transaction closed December 31, 2025 and became effective
The Simply Good Foods Company Reports Fiscal First Quarter 2026 Financial Results and Reaffirms Fiscal Year 2026 Outlook GlobeNewswire January 08, 2026 DENVER, Jan. 08, 2026 (GLOBE NEWSWIRE) — The Simply Good Foods Company (Nasdaq: SMPL) (“Simply Good Foods,” or the “Company”), a leader in the Nutritional Snacking Category, today reported financial results for the
Transpire Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 08, 2026 SUNRISE, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) — Transpire Bio announced today that its Chief Executive Officer, Dr. Xian-Ming Zeng, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 15, 2026 at
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 GlobeNewswire January 08, 2026 First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved regulatory clearance for SLE IND in China
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire January 08, 2026 Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outside North America Expected Year-End
Lantronix to Attend 28th Annual Needham Growth Conference on Jan. 13, 2026 GlobeNewswire January 08, 2026 IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global leader in compute and connectivity IoT solutions powering Edge AI applications, today announced that it will attend the 28th Annual Needham Growth Conference, held at
Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones GlobeNewswire January 08, 2026 Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended Phase 2 dose for CLN-049 pivotal registrational study and initiate combination study in
Troilus Delivers on Key Development Milestones in 2025 and Enters a Pivotal Transition Year in 2026 GlobeNewswire January 08, 2026 MONTREAL, Jan. 08, 2026 (GLOBE NEWSWIRE) — Troilus Mining Corp. (TSX: TLG; OTCQX: CHXMF; FRA: CM5) (“Troilus” or the “Company”), is pleased to provide a review of its key accomplishments in 2025 and an outlook
Kinross to provide update on Round Mountain Phase X, Kettle River-Curlew and Bald Mountain Redbird 2 projects GlobeNewswire January 08, 2026 TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) — Kinross Gold Corporation (TSX: K; NYSE: KGC) (“Kinross”) will provide an update on its Round Mountain Phase X, Kettle River-Curlew and Bald Mountain Redbird 2 projects, followed